SpeeDx Receives CARB-X Funding to Develop Rapid Point-of-Care Diagnostic

SpeeDx announced it has been awarded up to US $1.8 million from CARB-X to address the rising threat of drug-resistant bacteria.  Funds will be used to develop a rapid test for the combined detection of Chlamydia trachomatis and Neisseria gonorrhoeae, while identifying antimicrobial resistance (AMR) of gonorrhea infections towards common antibiotic treatments.  SpeeDx will utilize their newly patented InSignia technology to both assess the presence of active bacterial infection and AMR status. SpeeDx is collaborating with QuantuMDx to port the test onto their Q-POC sample to answer qPCR & integrated microarray system – a small battery-powered, simple-to-use device suitable for remote settings.     

“We are working closely with QuantuMDx to supply affordable and innovative diagnostics with the goal of significantly improving the standard of care and antibiotic stewardship in STI management,” said Colin Denver, SpeeDx CEO.